

Toni L Pitcher

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9412933/publications.pdf>

Version: 2024-02-01

32
papers

3,359
citations

430874

18
h-index

434195

31
g-index

37
all docs

37
docs citations

37
times ranked

6330
citing authors

#	ARTICLE	IF	CITATIONS
1	Extracellular vesicle biomarkers for cognitive impairment in Parkinson's disease. <i>Brain</i> , 2023, 146, 195-208.	7.6	35
2	Neuropsychiatric Symptoms Are Associated with Dementia in Parkinson's Disease but Not Predictive of it. <i>Movement Disorders Clinical Practice</i> , 2021, 8, 390-399.	1.5	9
3	Meta-analysis of genome-wide DNA methylation identifies shared associations across neurodegenerative disorders. <i>Genome Biology</i> , 2021, 22, 90.	8.8	49
4	International Multicenter Analysis of Brain Structure Across Clinical Stages of Parkinson's Disease. <i>Movement Disorders</i> , 2021, 36, 2583-2594.	3.9	54
5	A Multi-Step Model of Parkinson's Disease Pathogenesis. <i>Movement Disorders</i> , 2021, 36, 2530-2538.	3.9	13
6	Higher perceived stress and exacerbated motor symptoms in Parkinson's disease during the COVID-19 lockdown in New Zealand. <i>New Zealand Medical Journal</i> , 2021, 134, 44-51.	0.5	0
7	Nanopore sequencing of the glucocerebrosidase (GBA) gene in a New Zealand Parkinson's disease cohort. <i>Parkinsonism and Related Disorders</i> , 2020, 70, 36-41.	2.2	17
8	Genetic correlations and genome-wide associations of cortical structure in general population samples of 22,824 adults. <i>Nature Communications</i> , 2020, 11, 4796.	12.8	61
9	Childbirth and Delayed Parkinson's Onset: A Reproducible Nonbiological Artifact of Societal Change. <i>Movement Disorders</i> , 2020, 35, 1268-1271.	3.9	2
10	Changes of plasma cGP/IGF1 molar ratio with age is associated with cognitive status of Parkinson disease. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2020, 12, e12025.	2.4	5
11	Variations in the patterns of prevalence and therapy in Australasian Parkinson's disease patients of different ethnicities. <i>BMJ Neurology Open</i> , 2020, 2, e000033.	1.6	5
12	Common Variants Coregulate Expression of <i>GBA</i> and Modifier Genes to Delay Parkinson's Disease Onset. <i>Movement Disorders</i> , 2020, 35, 1346-1356.	3.9	30
13	Analysis of DNA methylation associates the cystine-glutamate antiporter SLC7A11 with risk of Parkinson's disease. <i>Nature Communications</i> , 2020, 11, 1238.	12.8	85
14	The genetic architecture of the human cerebral cortex. <i>Science</i> , 2020, 367, .	12.6	450
15	Positive Association of Ascorbate and Inverse Association of Urate with Cognitive Function in People with Parkinson's Disease. <i>Antioxidants</i> , 2020, 9, 906.	5.1	8
16	Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease: a meta-analysis of genome-wide association studies. <i>Lancet Neurology</i> , The, 2019, 18, 1091-1102.	10.2	1,414
17	Improved precision of epigenetic clock estimates across tissues and its implication for biological ageing. <i>Genome Medicine</i> , 2019, 11, 54.	8.2	191
18	Beta Amyloid Deposition Is Not Associated With Cognitive Impairment in Parkinson's Disease. <i>Frontiers in Neurology</i> , 2019, 10, 391.	2.4	50

#	ARTICLE	IF	CITATIONS
19	Brain activation during processing of genuine facial emotion in depression: Preliminary findings. <i>Journal of Affective Disorders</i> , 2018, 225, 91-96.	4.1	18
20	Parkinson's disease across ethnicities: A nationwide study in New Zealand. <i>Movement Disorders</i> , 2018, 33, 1440-1448.	3.9	17
21	Parkinson's in the oldest old: Impact on estimates of future disease burden. <i>Parkinsonism and Related Disorders</i> , 2017, 42, 78-84.	2.2	21
22	Caregiver burden is increased in Parkinson's disease with mild cognitive impairment (PD-MCI). <i>Translational Neurodegeneration</i> , 2017, 6, 17.	8.0	35
23	Different PD-MCI criteria and risk of dementia in Parkinson's disease: 4-year longitudinal study. <i>Npj Parkinson's Disease</i> , 2016, 2, 15027.	5.3	55
24	Metabolite ratios in the posterior cingulate cortex do not track cognitive decline in Parkinson's disease in a clinical setting. <i>Parkinsonism and Related Disorders</i> , 2016, 22, 54-61.	2.2	20
25	Tracking Parkinson's Disease over One Year with Multimodal Magnetic Resonance Imaging in a Group of Older Patients with Moderate Disease. <i>PLoS ONE</i> , 2015, 10, e0143923.	2.5	21
26	White matter microstructure deteriorates across cognitive stages in Parkinson disease. <i>Neurology</i> , 2013, 80, 1841-1849.	1.1	129
27	Grey matter atrophy in cognitively impaired Parkinson's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2012, 83, 188-194.	1.9	211
28	Reduced striatal volumes in Parkinson's disease: a magnetic resonance imaging study. <i>Translational Neurodegeneration</i> , 2012, 1, 17.	8.0	81
29	The influence of motor and cognitive impairment upon visually-guided saccades in Parkinson's disease. <i>Neuropsychologia</i> , 2012, 50, 3338-3347.	1.6	60
30	Enhanced high-frequency membrane potential fluctuations control spike output in striatal fast-spiking interneurons <i>in vivo</i> . <i>Journal of Physiology</i> , 2011, 589, 4365-4381.	2.9	22
31	Arterial spin labelling reveals an abnormal cerebral perfusion pattern in Parkinson's disease. <i>Brain</i> , 2011, 134, 845-855.	7.6	173
32	Differences in striatal spiny neuron action potentials between the spontaneously hypertensive and Wistar-Kyoto rat strains. <i>Neuroscience</i> , 2007, 146, 135-142.	2.3	7